中文
English
한국어
日本語
Español
Français
Русский
| 카탈로그 번호 | YP598016 | ||||
|---|---|---|---|---|---|
| 설명 |
Idarucizumab (YP598016) is a research-grade recombinant antibody targeting Dabigatran Etexilate Mesylate. Produced in mammalian cells with native-like glycosylation.
Highlights
|
||||
| 종 반응성 | General | ||||
| 응용 분야 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo | ||||
| 숙주 종 | Human | ||||
| 클론성 | Monoclonal | ||||
| 이소타입 | Fab-G1-kappa | ||||
| 발현 시스템 | Mammalian cells | ||||
| 타겟 | Dabigatran Etexilate Mesylate | ||||
| 내독소 수준 | < 10 EU/mg | ||||
| 순도 | >95% purity as determined by SDS-PAGE. | ||||
| 정제 | Protein A/G purified from cell culture supernatant. | ||||
| 등록번호 | CAS: 211915-06-9 | ||||
| 형태 | Liquid | ||||
| 저장 완충액 | 0.01M PBS pH 7.4 데이터시트 인쇄본 또는 로트별 COA에 기재된 구체적인 완충액 정보를 참조하세요. |
||||
| 제품 사용 정보 |
| ||||
| 안정성 및 저장 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. | ||||
| 대체 이름 | aDabi-Fab, anti-dabigatran, antidotefordabigatran, CAS: 1362509-93-0 | ||||
| 배경 | Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis. • Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial., PMID:33290737 • Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism., PMID:35699915 • The polymorph landscape of dabigatran etexilate mesylate: Taking the challenge to bring a metastable polymorph to market., PMID:37044200 • Dose tailoring of dabigatran etexilate: obvious or excessive?, PMID:25994994 • A Pharmacokinetic Evaluation of Dabigatran Etexilate, Total Dabigatran, and Unconjugated Dabigatran Following the Administration of Dabigatran Etexilate Mesylate Capsules in Healthy Male and Female Subjects., PMID:31652461 • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis., PMID:28693366 • Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation., PMID:28185082 • Direct oral anticoagulants: evidence and unresolved issues., PMID:33248499 • Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta., PMID:24807346 • The discovery of dabigatran etexilate for the treatment of venous thrombosis., PMID:27159158 | ||||
| 참고사항 | For research use only. Not suitable for clinical or therapeutic use. | ||||
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
SDS-PAGE for Research Grade Idarucizumab
+86-027-65523339
중국 우한시 심둔사로 666번지 C동, 우한, 430206
